Illinois Municipal Retirement Fund acquired a new stake in shares of Vericel Corporation (NASDAQ:VCEL – Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 26,679 shares of the biotechnology company’s stock, valued at approximately $1,071,000. Illinois Municipal Retirement Fund owned approximately 0.05% of Vericel at the end of the most recent quarter.
Other hedge funds also recently bought and sold shares of the company. MCF Advisors LLC lifted its stake in Vericel by 293.0% in the 2nd quarter. MCF Advisors LLC now owns 782 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 583 shares in the last quarter. Ameritas Advisory Services LLC acquired a new position in shares of Vericel during the 2nd quarter worth approximately $36,000. Allworth Financial LP purchased a new stake in shares of Vericel in the second quarter valued at approximately $60,000. Integrated Wealth Concepts LLC purchased a new stake in shares of Vericel in the second quarter valued at approximately $72,000. Finally, GAMMA Investing LLC grew its position in shares of Vericel by 17.7% in the second quarter. GAMMA Investing LLC now owns 1,886 shares of the biotechnology company’s stock valued at $84,000 after purchasing an additional 283 shares in the last quarter.
Insider Activity
In related news, insider Sean C. Flynn sold 15,000 shares of the stock in a transaction that occurred on Thursday, November 5th. The stock was sold at an average price of $51.92, for a total value of $778,800.00. Following the completion of the transaction, the insider directly owned 1,990 shares in the company, valued at approximately $103,320.80. This represents a 88.29% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Joseph Anthony Mara, Jr. sold 25,000 shares of the stock in a transaction that occurred on Monday, November 9th. The stock was sold at an average price of $58.26, for a total value of $1,456,500.00. Following the completion of the transaction, the chief financial officer owned 16,186 shares of the company’s stock, valued at $942,996.36. The trade was a 60.70% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 49,008 shares of company stock worth $2,701,078 in the last 90 days. 7.60% of the stock is owned by corporate insiders.
Vericel Price Performance
Shares of VCEL stock opened at $58.65 on Thursday. The company has a market capitalization of $2.99 billion, a PE ratio of 90.44 and a beta of 1.08. The firm’s 50-day moving average is $43.90 and its two-hundred day moving average is $39.73. Vericel Corporation has a 12 month low of $28.95 and a 12 month high of $59.75.
Vericel (NASDAQ:VCEL – Get Free Report) last posted its quarterly earnings results on Thursday, November 5th. The biotechnology company reported $0.27 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.21. The business had revenue of $85.37 million during the quarter, compared to analysts’ expectations of $77.95 million. Vericel had a net margin of 10.27% and a return on equity of 9.09%. The business’s revenue for the quarter was up 26.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.10 EPS. Sell-side analysts forecast that Vericel Corporation will post 0.78 EPS for the current year.
Analysts Set New Price Targets
Several equities research analysts recently commented on VCEL shares. Wall Street Zen raised Vericel from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 7th. HC Wainwright boosted their price objective on Vericel from $72.00 to $75.00 and gave the stock a “buy” rating in a research note on Friday, November 6th. TD Cowen boosted their price objective on Vericel from $55.00 to $58.00 and gave the stock a “buy” rating in a research note on Friday, July 31st. Truist Financial upped their target price on Vericel from $52.00 to $65.00 and gave the company a “buy” rating in a report on Friday, November 6th. Finally, Stephens raised their target price on Vericel from $55.00 to $68.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 10th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $62.00.
Check Out Our Latest Stock Report on Vericel
About Vericel
Vericel Corporation is a biopharmaceutical company focused on developing and commercializing cell therapies and other treatments for serious conditions. Based in Cambridge, Massachusetts, the company markets its products primarily in the United States. Its products include MACI, an implant made from a patient’s own cultured cartilage cells used to repair certain cartilage defects in the knee, and Epicel, a cultured skin graft used to treat patients with deep burns. Vericel also commercializes NexoBrid in the United States, an enzyme-based treatment for removing dead tissue from severe thermal burns.
Recommended Stories
- Five stocks we like better than Vericel
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Want to see what other hedge funds are holding VCEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vericel Corporation (NASDAQ:VCEL – Free Report).
Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.
